Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 15 | 2024 | 1324 | 1.260 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 10 | 2024 | 85 | 1.060 |
Why?
|
| HIV Infections | 22 | 2024 | 5097 | 1.050 |
Why?
|
| Oxazines | 10 | 2024 | 81 | 0.950 |
Why?
|
| Pyridones | 10 | 2024 | 100 | 0.930 |
Why?
|
| Piperazines | 9 | 2024 | 82 | 0.900 |
Why?
|
| HIV-1 | 10 | 2024 | 1260 | 0.730 |
Why?
|
| Tenofovir | 7 | 2024 | 171 | 0.590 |
Why?
|
| Weight Gain | 4 | 2024 | 77 | 0.510 |
Why?
|
| Benzoxazines | 5 | 2024 | 123 | 0.410 |
Why?
|
| Alkynes | 4 | 2024 | 117 | 0.370 |
Why?
|
| Cyclopropanes | 4 | 2024 | 123 | 0.370 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2024 | 472 | 0.330 |
Why?
|
| Humans | 24 | 2024 | 14537 | 0.320 |
Why?
|
| Female | 19 | 2024 | 9103 | 0.300 |
Why?
|
| Adult | 16 | 2024 | 5913 | 0.300 |
Why?
|
| HIV Integrase Inhibitors | 3 | 2024 | 33 | 0.270 |
Why?
|
| Creatinine | 2 | 2024 | 53 | 0.260 |
Why?
|
| Adenine | 3 | 2023 | 91 | 0.250 |
Why?
|
| Emtricitabine | 5 | 2024 | 78 | 0.240 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2019 | 656 | 0.240 |
Why?
|
| Triazoles | 1 | 2024 | 20 | 0.240 |
Why?
|
| Viral Load | 4 | 2020 | 819 | 0.220 |
Why?
|
| Male | 11 | 2024 | 6754 | 0.220 |
Why?
|
| Antiviral Agents | 3 | 2022 | 111 | 0.220 |
Why?
|
| Chronic Pain | 1 | 2022 | 3 | 0.210 |
Why?
|
| Pharmacogenetics | 1 | 2022 | 31 | 0.200 |
Why?
|
| Herpesvirus 2, Human | 3 | 2012 | 43 | 0.190 |
Why?
|
| Blood Pressure | 1 | 2024 | 317 | 0.190 |
Why?
|
| Herpes Genitalis | 3 | 2012 | 43 | 0.190 |
Why?
|
| Middle Aged | 8 | 2024 | 3601 | 0.190 |
Why?
|
| Folic Acid | 1 | 2021 | 12 | 0.180 |
Why?
|
| Drug Interactions | 1 | 2021 | 31 | 0.180 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2020 | 41 | 0.180 |
Why?
|
| Acyclovir | 2 | 2012 | 11 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 187 | 0.180 |
Why?
|
| Pain | 1 | 2020 | 41 | 0.180 |
Why?
|
| Cost-Benefit Analysis | 2 | 2021 | 253 | 0.170 |
Why?
|
| South Africa | 9 | 2024 | 7596 | 0.170 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.160 |
Why?
|
| Hypertension | 1 | 2024 | 419 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2019 | 38 | 0.160 |
Why?
|
| Kidney | 1 | 2019 | 46 | 0.160 |
Why?
|
| Stavudine | 1 | 2019 | 78 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2018 | 151 | 0.140 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 56 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2022 | 889 | 0.130 |
Why?
|
| RNA, Viral | 3 | 2019 | 303 | 0.130 |
Why?
|
| Hepatitis B | 1 | 2017 | 125 | 0.130 |
Why?
|
| Mass Screening | 1 | 2017 | 245 | 0.120 |
Why?
|
| Coinfection | 1 | 2017 | 276 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 551 | 0.120 |
Why?
|
| DNA, Viral | 3 | 2012 | 165 | 0.120 |
Why?
|
| Young Adult | 6 | 2020 | 2498 | 0.110 |
Why?
|
| Lamivudine | 2 | 2024 | 89 | 0.110 |
Why?
|
| Alanine | 2 | 2024 | 31 | 0.100 |
Why?
|
| Ulcer | 1 | 2012 | 7 | 0.100 |
Why?
|
| Darunavir | 2 | 2022 | 12 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2019 | 529 | 0.090 |
Why?
|
| Lopinavir | 2 | 2022 | 137 | 0.090 |
Why?
|
| Ritonavir | 2 | 2022 | 137 | 0.090 |
Why?
|
| Contraception | 1 | 2010 | 90 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2019 | 272 | 0.080 |
Why?
|
| Genitalia, Female | 1 | 2008 | 17 | 0.080 |
Why?
|
| Drug Resistance, Viral | 2 | 2020 | 278 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2020 | 967 | 0.070 |
Why?
|
| Pregnancy | 3 | 2021 | 1862 | 0.070 |
Why?
|
| HIV | 1 | 2010 | 380 | 0.070 |
Why?
|
| Adolescent | 3 | 2020 | 2985 | 0.060 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 353 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2024 | 33 | 0.060 |
Why?
|
| Glucuronosyltransferase | 1 | 2024 | 6 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 62 | 0.060 |
Why?
|
| Nitro Compounds | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2022 | 4 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 9 | 0.050 |
Why?
|
| Thiazoles | 1 | 2022 | 6 | 0.050 |
Why?
|
| Sofosbuvir | 1 | 2022 | 8 | 0.050 |
Why?
|
| Valine | 1 | 2022 | 6 | 0.050 |
Why?
|
| Carbamates | 1 | 2022 | 12 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 198 | 0.050 |
Why?
|
| Social Stigma | 1 | 2022 | 80 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2021 | 16 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 112 | 0.050 |
Why?
|
| HIV Integrase | 1 | 2020 | 6 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 244 | 0.050 |
Why?
|
| Virus Shedding | 2 | 2012 | 24 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 177 | 0.040 |
Why?
|
| Exercise | 1 | 2022 | 205 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 442 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 111 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Prodrugs | 1 | 2019 | 10 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 306 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 153 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 7 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 435 | 0.040 |
Why?
|
| Cervix Uteri | 2 | 2009 | 22 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 107 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 279 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 197 | 0.040 |
Why?
|
| Vagina | 2 | 2009 | 91 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2018 | 16 | 0.040 |
Why?
|
| Specimen Handling | 2 | 2009 | 105 | 0.040 |
Why?
|
| Transaminases | 1 | 2017 | 5 | 0.040 |
Why?
|
| Antigens | 1 | 2017 | 11 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 9 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 91 | 0.040 |
Why?
|
| Albuminuria | 1 | 2017 | 20 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 217 | 0.040 |
Why?
|
| Cities | 1 | 2017 | 37 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2017 | 40 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 41 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1192 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 115 | 0.030 |
Why?
|
| Aged | 1 | 2019 | 1740 | 0.030 |
Why?
|
| Recurrence | 1 | 2012 | 29 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 106 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2012 | 52 | 0.020 |
Why?
|
| Zambia | 1 | 2012 | 115 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2012 | 109 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 163 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 2008 | 4 | 0.020 |
Why?
|
| Menstrual Hygiene Products | 1 | 2008 | 8 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 370 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 685 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2009 | 320 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 1475 | 0.020 |
Why?
|